Phase 2Enrolling by invitation
Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults (AFFIRM-LITE)
AFFIRM-LITE: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults
- Sponsor
- Mayo Clinic (Academic or other)
- Enrolment
- 40 planned
- Conditions
- Frail Elderly Syndrome
- Interventions
- Fisetin; Placebo oral capsule
- Ages
- older adults
- Registry
- NCT03675724
From the registry
This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone resorption in elderly adults.
Primary outcomes
- Decrease in blood inflammation markers